Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Acrylamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.65 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.59 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GABRR2 | P28476 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylamide SCHEMBL1417837 | 1.00 | TSHR (0.65) | TSHRALDH1A1FGFR4GLRA1SLC6A9 | |
| Acrylamide SCHEMBL28362017 | 0.85 | ALDH1A1 (0.69) | TSHRALDH1A1FGFR4GLRA1SLC6A9 | |
| Acrylic Acid SCHEMBL27586368 | 0.85 | LMNA (0.62) | TSHRALDH1A1FGFR4GLRA1SLC6A9 | |
| Acrylamide SCHEMBL28209083 | 0.84 | TSHR (0.92) | TSHRALDH1A1FGFR4OR51E2LMNA | |
| Malonic Acid SCHEMBL2437426 | 0.82 | TSHR (0.65) | TSHRALDH1A1FGFR4GLRA1SLC6A9 | |
| Succinic Acid SCHEMBL28213422 | 0.82 | TSHR (0.65) | TSHRALDH1A1FGFR4OR51E2LMNA | |
| Succinic Acid SCHEMBL28443304 | 0.82 | TSHR (0.65) | TSHRALDH1A1FGFR4OR51E2LMNA | |
| Malonic Acid SCHEMBL27781561 | 0.82 | TSHR (0.65) | TSHRALDH1A1FGFR4GLRA1SLC6A9 | |
| Acrylamide SCHEMBL29083279 | 0.82 | ALDH1A1 (0.65) | TSHRALDH1A1FGFR4GLRA1SLC6A9 | |
| Acrylamide SCHEMBL28238685 | 0.82 | ALDH1A1 (0.65) | TSHRALDH1A1FGFR4GLRA1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137792-A1 | CYTOTOXIC NECROTIZING FACTORS AS EXOGENOUS CARRIERS IN MAMMALIAN CELLS | SE THERAPEUTICS (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12491161-B2 | Single vial vaccine formulations | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250295591-A1 | SINGLE VIAL VACCINE FORMULATIONS | ACCESS TO ADVANCED HEALTH INST (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4601668-A1 | CYTOTOXIC NECROTIZING FACTORS AS EXOGENOUS CARRIERS IN MAMMALIAN CELLS | SE Therapeutics (FR) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025040815-A1 | BIOSENSORS FOR MONITORING CELLULAR STRESS | CLONEOPT AB (SE) | 2025-02-27 | — | — | WO | disclosed |
| EP-4211454-B1 | SAW-BASED HYDROGEL TESTING FOR DETECTING VIRUSES OR OTHER ANTIGENS | RAYTHEON CO (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024078828-A1 | CYTOTOXIC NECROTIZING FACTORS AS EXOGENOUS CARRIERS IN MAMMALIAN CELLS | SE THERAPEUTICS (FR) | 2024-04-18 | — | — | WO | disclosed |
| US-11898987-B2 | SAW-based hydrogel testing for detecting viruses or other antigens | RAYTHEON COMPANY (US) | 2024-02-13 | — | — | US | disclosed |
| US-11801223-B2 | Single vial vaccine formulations | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230293440-A1 | SINGLE VIAL VACCINE FORMULATIONS | ACCESS TO ADVANCED HEALTH INSTITUTE | 2023-09-21 | — | — | US | disclosed |
| WO-2002102989-A2 | METHOD FOR NEURAL STEM CELL DIFFERENTIATION USING VALPROATE | PSYCHIATRIC GENOMICS, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-6492509-B1 | NUCLEIC ACID SEQUENCES ENCODING FOR FATTY ACYL-COA: FATTY ALCOHOL ACYLTRANSFERASE (WAX SYNTHASE) ARE PROVIDED | CALGENE LLC | 2002-12-10 | — | — | US | disclosed |
| EP-1135474-A2 | FATTY ACYL-CoA: FATTY ALCOHOL ACYLTRANSFERASES | Calgene LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| CN-1301304-A | Fatty acyl coenzyme A fatty alcohol acyltransferase | CALGENE LLC (US) | 2001-06-27 | — | — | CN | disclosed |
| WO-2000036095-A2 | FATTY ACYL-CoA: FATTY ALCOHOL ACYLTRANSFERASES | CALGENE LLC (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000032793-A2 | PLANT CELL DERIVED DIACYLGLYCEROL ACYLTRANSFERASES | CALGENE LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-1003882-A1 | DIACYLGLYCEROL ACYL TRANSFERASE PROTEINS | Calgene LLC (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0986647-A1 | FATTY ACYL-CoA: FATTY ALCOHOL ACYLTRANSFERASES | Calgene LLC (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998055631-A1 | DIACYLGLYCEROL ACYL TRANSFERASE PROTEINS | CALGENE LLC (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998055632-A1 | FATTY ACYL-CoA: FATTY ALCOHOL ACYLTRANSFERASES | CALGENE LLC (US) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491161-B2 | Single vial vaccine formulations | SQLE, ICOS, IL17A | TSHR 4201/4885ALDH1A1 2219/4885FGFR4 4441/4885 |
| US-11801223-B2 | Single vial vaccine formulations | SQLE, ICOS, IL17A | TSHR 4201/4885ALDH1A1 2219/4885FGFR4 4441/4885 |
| US-20260137792-A1 | CYTOTOXIC NECROTIZING FACTORS AS EXOGENOUS CARRIERS IN MAMMALIAN CELLS | NCF1, HCFC1, ETF1 | TSHR 4351/4885ALDH1A1 4882/4885FGFR4 4500/4885 |
| US-20250295591-A1 | SINGLE VIAL VACCINE FORMULATIONS | SQLE, ICOS, IL17A | TSHR 4201/4885ALDH1A1 2219/4885FGFR4 4441/4885 |
| US-20230293440-A1 | SINGLE VIAL VACCINE FORMULATIONS | SQLE, ICOS, IL17A | TSHR 4201/4885ALDH1A1 2219/4885FGFR4 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.